 Michael Strong
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 24 | 2023 | 337 | 5.500 |
Why?
| | Genome, Bacterial | 13 | 2021 | 106 | 4.010 |
Why?
| | Mycobacterium | 11 | 2023 | 103 | 3.900 |
Why?
| | Mycobacterium tuberculosis | 18 | 2023 | 271 | 2.920 |
Why?
| | Nontuberculous Mycobacteria | 15 | 2023 | 207 | 2.670 |
Why?
| | Mycobacterium abscessus | 10 | 2023 | 98 | 2.230 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 61 | 1.700 |
Why?
| | Tuberculosis | 8 | 2023 | 244 | 1.440 |
Why?
| | Cystic Fibrosis | 11 | 2023 | 957 | 1.290 |
Why?
| | Phylogeny | 14 | 2021 | 805 | 1.200 |
Why?
| | Genomics | 5 | 2021 | 646 | 1.060 |
Why?
| | Antitubercular Agents | 8 | 2023 | 170 | 1.060 |
Why?
| | Genome, Viral | 3 | 2021 | 121 | 1.020 |
Why?
| | Bacteriophages | 3 | 2022 | 76 | 0.980 |
Why?
| | Lung Diseases | 3 | 2022 | 710 | 0.950 |
Why?
| | Methylobacterium | 1 | 2023 | 4 | 0.910 |
Why?
| | Computational Biology | 7 | 2018 | 536 | 0.860 |
Why?
| | Genetic Variation | 7 | 2021 | 878 | 0.780 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 56 | 0.760 |
Why?
| | Whole Genome Sequencing | 2 | 2021 | 100 | 0.760 |
Why?
| | Databases, Genetic | 3 | 2018 | 208 | 0.740 |
Why?
| | Sequence Analysis, DNA | 7 | 2022 | 732 | 0.740 |
Why?
| | Lysogeny | 1 | 2020 | 3 | 0.740 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 94 | 0.730 |
Why?
| | Prophages | 1 | 2020 | 4 | 0.730 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 608 | 0.730 |
Why?
| | Bacterial Proteins | 10 | 2016 | 739 | 0.730 |
Why?
| | Viruses | 1 | 2021 | 94 | 0.700 |
Why?
| | Plasmids | 1 | 2020 | 345 | 0.690 |
Why?
| | Mutation | 3 | 2021 | 3364 | 0.650 |
Why?
| | Hawaii | 5 | 2023 | 38 | 0.640 |
Why?
| | Soil Microbiology | 2 | 2020 | 176 | 0.630 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 1918 | 0.620 |
Why?
| | Drug Resistance, Bacterial | 7 | 2021 | 156 | 0.610 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 413 | 0.570 |
Why?
| | Respiratory System | 1 | 2017 | 141 | 0.540 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 250 | 0.540 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 62 | 0.520 |
Why?
| | Software | 4 | 2022 | 541 | 0.520 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 317 | 0.520 |
Why?
| | Cross Infection | 3 | 2021 | 202 | 0.460 |
Why?
| | Microbiota | 1 | 2021 | 652 | 0.460 |
Why?
| | Systems Biology | 1 | 2014 | 57 | 0.450 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 24 | 0.440 |
Why?
| | DNA, Bacterial | 4 | 2021 | 309 | 0.440 |
Why?
| | Humans | 51 | 2023 | 115589 | 0.440 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 112 | 0.430 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 142 | 0.420 |
Why?
| | Molybdenum | 2 | 2021 | 8 | 0.380 |
Why?
| | Genotype | 4 | 2019 | 1787 | 0.370 |
Why?
| | Metagenomics | 2 | 2021 | 131 | 0.360 |
Why?
| | Sputum | 6 | 2021 | 290 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 2 | 2016 | 2125 | 0.350 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 299 | 0.350 |
Why?
| | Lung | 6 | 2023 | 3672 | 0.330 |
Why?
| | RNA | 1 | 2014 | 819 | 0.300 |
Why?
| | Genes, Bacterial | 4 | 2017 | 156 | 0.280 |
Why?
| | United States | 9 | 2022 | 12295 | 0.280 |
Why?
| | Chromosome Mapping | 2 | 2023 | 489 | 0.270 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 41 | 0.260 |
Why?
| | Disease Outbreaks | 2 | 2021 | 308 | 0.260 |
Why?
| | Proteomics | 3 | 2006 | 859 | 0.250 |
Why?
| | Proteins | 2 | 2013 | 920 | 0.250 |
Why?
| | Cluster Analysis | 4 | 2014 | 465 | 0.250 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 46 | 0.250 |
Why?
| | Soil | 3 | 2022 | 171 | 0.240 |
Why?
| | Evolution, Molecular | 2 | 2021 | 440 | 0.240 |
Why?
| | Virulence | 3 | 2020 | 231 | 0.240 |
Why?
| | Data Accuracy | 1 | 2023 | 49 | 0.220 |
Why?
| | Multigene Family | 1 | 2003 | 193 | 0.220 |
Why?
| | Immunity, Innate | 2 | 2021 | 731 | 0.210 |
Why?
| | Gene Expression Regulation, Bacterial | 5 | 2023 | 284 | 0.210 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 16 | 0.200 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 14 | 0.200 |
Why?
| | Furin | 1 | 2021 | 13 | 0.200 |
Why?
| | Asia | 1 | 2021 | 53 | 0.200 |
Why?
| | Gene Expression Profiling | 7 | 2023 | 1536 | 0.200 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 49 | 0.200 |
Why?
| | Africa | 1 | 2021 | 96 | 0.190 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 47 | 0.190 |
Why?
| | Alanine | 1 | 2021 | 103 | 0.190 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 102 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 443 | 0.190 |
Why?
| | Genome Size | 1 | 2020 | 10 | 0.190 |
Why?
| | Models, Molecular | 3 | 2016 | 1390 | 0.190 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 135 | 0.190 |
Why?
| | Europe | 1 | 2021 | 336 | 0.190 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 267 | 0.180 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 383 | 0.180 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 511 | 0.180 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 65 | 0.180 |
Why?
| | Water Pollution | 1 | 2020 | 7 | 0.180 |
Why?
| | Metagenome | 1 | 2021 | 122 | 0.180 |
Why?
| | Water Quality | 1 | 2020 | 30 | 0.180 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 112 | 0.170 |
Why?
| | Adaptation, Physiological | 3 | 2023 | 476 | 0.170 |
Why?
| | Immune Evasion | 1 | 2020 | 47 | 0.170 |
Why?
| | Protein Binding | 2 | 2021 | 1917 | 0.170 |
Why?
| | Pneumonia | 2 | 2023 | 576 | 0.170 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 76 | 0.170 |
Why?
| | Databases, Factual | 2 | 2021 | 1138 | 0.170 |
Why?
| | Membrane Lipids | 1 | 2020 | 87 | 0.170 |
Why?
| | Protein Conformation | 2 | 2016 | 822 | 0.160 |
Why?
| | Binding Sites | 1 | 2021 | 1177 | 0.160 |
Why?
| | Phospholipids | 1 | 2020 | 202 | 0.160 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1483 | 0.150 |
Why?
| | Mycolic Acids | 1 | 2017 | 6 | 0.150 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.150 |
Why?
| | Virus Diseases | 1 | 2020 | 200 | 0.150 |
Why?
| | Transcriptome | 3 | 2023 | 736 | 0.150 |
Why?
| | Base Composition | 1 | 2017 | 76 | 0.150 |
Why?
| | Oregon | 1 | 2017 | 66 | 0.150 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 95 | 0.150 |
Why?
| | Water Supply | 1 | 2017 | 71 | 0.140 |
Why?
| | Brazil | 2 | 2014 | 93 | 0.140 |
Why?
| | Surgical Equipment | 1 | 2016 | 13 | 0.140 |
Why?
| | RNA, Viral | 1 | 2020 | 565 | 0.140 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.140 |
Why?
| | Gene Expression | 1 | 2021 | 1436 | 0.140 |
Why?
| | Equipment Contamination | 1 | 2016 | 54 | 0.140 |
Why?
| | Fluoroquinolones | 1 | 2016 | 41 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2021 | 651 | 0.130 |
Why?
| | Web Browser | 1 | 2015 | 12 | 0.130 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 17 | 0.130 |
Why?
| | Catalase | 1 | 2016 | 118 | 0.130 |
Why?
| | Gene Ontology | 1 | 2015 | 47 | 0.130 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 82 | 0.130 |
Why?
| | Isoniazid | 1 | 2016 | 52 | 0.130 |
Why?
| | Housing | 1 | 2016 | 114 | 0.130 |
Why?
| | Rifampin | 1 | 2016 | 68 | 0.130 |
Why?
| | Bacterial Toxins | 1 | 2016 | 103 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 489 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 372 | 0.120 |
Why?
| | Data Mining | 1 | 2016 | 100 | 0.120 |
Why?
| | Viral Core Proteins | 1 | 2014 | 20 | 0.120 |
Why?
| | Adaptive Immunity | 1 | 2016 | 157 | 0.120 |
Why?
| | Biofilms | 1 | 2016 | 222 | 0.120 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 3 | 0.120 |
Why?
| | Genetic Linkage | 2 | 2006 | 297 | 0.120 |
Why?
| | DNA Repeat Expansion | 1 | 2013 | 5 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 511 | 0.110 |
Why?
| | Transcription, Genetic | 5 | 2023 | 1310 | 0.110 |
Why?
| | Operon | 2 | 2003 | 59 | 0.110 |
Why?
| | Phenotype | 3 | 2016 | 2829 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2003 | 219 | 0.110 |
Why?
| | Galectins | 1 | 2013 | 22 | 0.110 |
Why?
| | Virulence Factors | 1 | 2014 | 139 | 0.100 |
Why?
| | Hepacivirus | 1 | 2014 | 234 | 0.100 |
Why?
| | Epidemics | 1 | 2013 | 70 | 0.100 |
Why?
| | Biomedical Research | 1 | 2018 | 588 | 0.100 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 123 | 0.100 |
Why?
| | Neurodegenerative Diseases | 1 | 2013 | 92 | 0.100 |
Why?
| | Adult | 9 | 2023 | 30719 | 0.100 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 138 | 0.100 |
Why?
| | Colorado | 4 | 2022 | 4113 | 0.090 |
Why?
| | DNA, Viral | 1 | 2012 | 351 | 0.090 |
Why?
| | Time Factors | 2 | 2021 | 6165 | 0.090 |
Why?
| | Base Sequence | 1 | 2013 | 2114 | 0.090 |
Why?
| | Aged | 6 | 2021 | 19250 | 0.080 |
Why?
| | Species Specificity | 2 | 2020 | 552 | 0.080 |
Why?
| | Middle Aged | 7 | 2021 | 26998 | 0.080 |
Why?
| | Signal Transduction | 2 | 2016 | 4541 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2021 | 3022 | 0.080 |
Why?
| | Public Health | 1 | 2012 | 438 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2021 | 334 | 0.070 |
Why?
| | Cell Wall | 2 | 2006 | 50 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2353 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2023 | 3580 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4435 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6417 | 0.070 |
Why?
| | Treatment Failure | 2 | 2021 | 332 | 0.070 |
Why?
| | Uganda | 2 | 2016 | 68 | 0.070 |
Why?
| | Solubility | 1 | 2006 | 226 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 3467 | 0.060 |
Why?
| | Female | 8 | 2023 | 59913 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2006 | 523 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2016 | 9159 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 408 | 0.060 |
Why?
| | Iron | 2 | 2022 | 235 | 0.060 |
Why?
| | Protein Kinases | 2 | 2016 | 306 | 0.060 |
Why?
| | Male | 7 | 2022 | 55949 | 0.060 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 5 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2800 | 0.060 |
Why?
| | Proteome | 2 | 2006 | 345 | 0.060 |
Why?
| | Galactans | 1 | 2003 | 4 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 746 | 0.060 |
Why?
| | Genome | 1 | 2006 | 271 | 0.060 |
Why?
| | Dust | 1 | 2023 | 84 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 198 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 92 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2473 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 701 | 0.050 |
Why?
| | Oxides | 1 | 2022 | 42 | 0.050 |
Why?
| | Clarithromycin | 1 | 2021 | 25 | 0.050 |
Why?
| | Macrophages | 2 | 2020 | 1284 | 0.050 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.050 |
Why?
| | Macrolides | 1 | 2021 | 56 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 7 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 248 | 0.050 |
Why?
| | Cell Membrane | 2 | 2020 | 683 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 163 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 962 | 0.050 |
Why?
| | Bioreactors | 1 | 2021 | 45 | 0.050 |
Why?
| | Smokers | 1 | 2021 | 147 | 0.050 |
Why?
| | Water | 1 | 2023 | 412 | 0.050 |
Why?
| | Microbial Viability | 1 | 2021 | 79 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 24 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 20 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 37 | 0.040 |
Why?
| | Cathelicidins | 1 | 2020 | 39 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2023 | 4773 | 0.040 |
Why?
| | Genetics, Population | 1 | 2021 | 192 | 0.040 |
Why?
| | DNA-Binding Proteins | 2 | 2016 | 1316 | 0.040 |
Why?
| | Mice | 3 | 2023 | 15052 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 290 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 639 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 2574 | 0.040 |
Why?
| | Animals | 4 | 2023 | 32102 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 585 | 0.040 |
Why?
| | Gambia | 1 | 2016 | 12 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 357 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 844 | 0.030 |
Why?
| | Risk Factors | 2 | 2021 | 8697 | 0.030 |
Why?
| | Regulon | 1 | 2016 | 33 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 47 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 69 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 730 | 0.030 |
Why?
| | India | 1 | 2016 | 135 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 10470 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 85 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2264 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 17890 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 173 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 156 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 184 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 64 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 34 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2016 | 296 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 12 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 451 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 79 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2017 | 378 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 122 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 151 | 0.030 |
Why?
| | C9orf72 Protein | 1 | 2013 | 9 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1440 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 305 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1086 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2014 | 277 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 86 | 0.030 |
Why?
| | United Kingdom | 1 | 2014 | 227 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1000 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 123 | 0.030 |
Why?
| | Muromegalovirus | 1 | 2013 | 13 | 0.030 |
Why?
| | tau Proteins | 1 | 2013 | 67 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 26 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2013 | 75 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 231 | 0.030 |
Why?
| | Interleukin-15 | 1 | 2013 | 76 | 0.030 |
Why?
| | Interleukin-12 | 1 | 2013 | 110 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 6264 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 174 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 355 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 350 | 0.020 |
Why?
| | Hepatitis C | 1 | 2014 | 229 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 124 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 382 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 286 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 937 | 0.020 |
Why?
| | Child | 2 | 2021 | 18489 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2790 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1024 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 2604 | 0.020 |
Why?
| | Vaccination | 1 | 2014 | 1209 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 3914 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2021 | 12608 | 0.020 |
Why?
| | Biological Transport | 1 | 2006 | 375 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4440 | 0.020 |
Why?
| | DNA Repair | 1 | 2006 | 190 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 4944 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 449 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 820 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 454 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|